leadf
logo-loader
viewTissue Regenix Group PLC

Tissue Regenix develops new product line in collaboration with global healthcare giant

Tissue Regenix said it expects the newly developed product line will make a material contribution to its revenue growth over the next couple of years.

Tissue Regenix Group PLC -

 

Tissue Regenix Group PLC (LON:TRX) has entered a new strategic collaboration for white label manufacturing with a leading top 10 global healthcare company.

The manufacturing agreement follows a collaboration between the research and development (R&D( teams of both companies to develop a new product using one of the Tissue Regenix’s proprietary technologies to address orthopaedic soft tissue repairs.

Processing for the product has begun, and initial orders have been received.

Tissue Regenix said it expects the newly developed product line will make a material contribution to its revenue growth over the next couple of years.

This new product line is complementary to the other soft tissue products processed at the San Antonio facility, and due to operational efficiencies implemented, it is not expected that there will be any impact on the current processing levels of other product lines.

The company also announced that it signed further distribution agreements in the first quarter of this year with a number of selected partners to expand the market penetration of its AmnioWorks, Matrix OI, and DentalFix brands in areas such as ocular, spinal, and dental, where there is an increasing demand for the differentiated product lines.

"This exciting opportunity will allow Tissue Regenix to drive its commercial strategy forward and ensure the continued growth of the business with minimal impact to our existing strategic partners and customer base,” said Gareth Jones, the interim chief 3executive officer of Tissue Regenix.

“Securing these important partnerships and distribution agreements underscore the differentiation of, and increasing market demand for, our products; providing further validation of the exciting growth potential for the business once we have completed the planned expansion of our processing capacity," he added.

Quick facts: Tissue Regenix Group PLC

Price: 0.33 GBX

AIM:TRX
Market: AIM
Market Cap: £23.21 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Tissue Regenix Group PLC named herein, including the promotion by the Company of Tissue Regenix Group PLC in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Tissue Regenix "advancing on many fronts" says CEO after SurgiPure FDA clearance

Antony Odell, chief executive at Tissue Regenix (LON:TRX), talks to Proactive Investors about the US FDA clearance for SurgiPure XD, a skin graft for hernias derived from pig tissue. The group, which already has experience of commercialising products in the US, is planning a commercial...

on 03/09/2016

2 min read